A Two Part Bioequivalence Study to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR 5/500 mg (Part 1) and 10/1000 mg (Part 2) Manufactured at Two Different Plants in Healthy Subjects Under Fasting and Fed Conditions
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2018
At a glance
- Drugs Dapagliflozin/metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 11 Apr 2016 Status changed from recruiting to completed.
- 05 Jan 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 24 Dec 2015 New trial record